The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Dec. 14, 2021
Applicant:

The Trustees of Columbia University IN the City of New York, New York, NY (US);

Inventors:

Chelsea Dieck, New York, NY (US);

Adolfo Ferrando, New York, NY (US);

Arie Zask, New York, NY (US);

Brent Stockwell, New York, NY (US);

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/5415 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61K 31/4184 (2006.01); A61K 31/428 (2006.01); A61K 31/4704 (2006.01); A61K 45/06 (2006.01); C07D 217/26 (2006.01); C07D 333/66 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 409/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5415 (2013.01); A61K 31/381 (2013.01); A61K 31/4025 (2013.01); A61K 31/4184 (2013.01); A61K 31/428 (2013.01); A61K 31/4704 (2013.01); A61K 45/06 (2013.01); C07D 217/26 (2013.01); C07D 333/66 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 409/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 495/04 (2013.01);
Abstract

Various embodiments relate to compounds, having structures according to Structure A or Structure B, as specified herein. The compounds according to various embodiments may inhibit NT5C2 nucleotidase. The compounds according to various embodiments may synergistically decrease cell viability of NT5C2 R367Q mutant lymphoblasts when used in combination with 6-mercaptopurine (6-MP) to treat a cancer. The cancer may be, but is not limited to, acute lymphoblastic leukemia. Various embodiments relate to a compositions that may include one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof and a pharmaceutically acceptable carrier. Various embodiments relate to methods of treating cancer. The method may comprise administering a therapeutically effective amount of one or more compounds according to any embodiment described herein or a pharmaceutically acceptable salt or derivative thereof.


Find Patent Forward Citations

Loading…